Skip to Main Content
Contribute Try STAT+ Today

WASHINGTON — The Biotechnology Innovation Organization filed a lawsuit Friday to block implementation of President Trump’s new policy to lower drug prices, the organization tells STAT.

The “most favored nations” policy, which was unveiled late last month, would peg what Medicare pays for 50 pricey injectable drugs to the lowest price paid in countries like Japan and Belgium. The change could cut reimbursement for some of the best-selling drugs in America, in half, or more.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Given the procedural flaws in this administration move, obviously tied to election strategy and based on a fragile legal rationale, this seems likely to get decided not on policy substance but on procedure, pushing the debate about the underlying policy into the Biden Administration. To be continued…

Comments are closed.